The New York University Cancer Institute (NYUCI) is seeking funding for its 26th year as an NCI-designated cancer center following a significant re-vitalization of cancer research and treatment activities on the NYU Medical Center campuses that was initiated in 1998. With the recruitment of Dr. Steven Burakoff in 2000 the NYUCI has undergone major expansion. Growth in facilities, faculty recruitment, research productivity, and clinical care has exceeded the benchmarks outlined in strategic plan articulated in the 2002 renewal. During the last funding period, twenty-four faculty in basic, translational and clinical research have been recruited to the NYUCI. Facilities to house research and treatment programs have expanded 400% with the opening the new NYU Clinical Cancer Center and the NYUCI Research Laboratories located within the new Smilow Research Center. Extramural funding has doubled to $64,087,423 (total) in peer reviewed funding and a overall research base of $75,898,561. Funding from the NCI has also doubled and now totals $19,750,445. The Cancer Center Support Grant (CCSG) builds on many unique institutional strengths of this metropolitan hospital center with a highly diverse faculty, staff and patient population. In the current application seven scientific programs are presented for consideration: Cancer Immunology and Immunotherapy, Growth Control, Cancer Stem Cells, Molecular and Environmental Carcinogenesis, Melanoma, Breast Cancer and Genitourinary Cancer. Ten shared resources are supported by the CCSG and two new cores, Vaccine and Cancer Genomics, are presented in the application. The Clinical Trials Office has supported the growth of NYU investigator-initiated studies which now account for 68.7% of all therapeutic accruals. Overall accruals have increased steadily over the past three years from 9.25% in 2004 to 13.3% (projected) in 2006. The NYUCI has fostered an environment that promotes research collaborations and multidisciplinary patient care with 24% of all publications being intra- or interprogrammatic (12% each). The CCSG application continues to be actively supported by the President of NYU, the Dean and CEO of NYU Medical Center, and Hospital and Community leadership who pledge additional resources.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016087-29S1
Application #
7847344
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
2009-06-01
Project End
2011-09-30
Budget Start
2009-06-01
Budget End
2011-09-30
Support Year
29
Fiscal Year
2009
Total Cost
$93,456
Indirect Cost
Name
New York University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Snetkova, Valentina; Skok, Jane A (2018) Enhancer talk. Epigenomics 10:483-498
Litwinoff, Evelyn M S; Gold, Merav Y; Singh, Karan et al. (2018) Myeloid ATG16L1 does not affect adipose tissue inflammation or body mass in mice fed high fat diet. Obes Res Clin Pract 12:174-186
Gregory, Ann C; Sullivan, Matthew B; Segal, Leopoldo N et al. (2018) Smoking is associated with quantifiable differences in the human lung DNA virome and metabolome. Respir Res 19:174
Lee, Chul-Hwan; Holder, Marlene; Grau, Daniel et al. (2018) Distinct Stimulatory Mechanisms Regulate the Catalytic Activity of Polycomb Repressive Complex 2. Mol Cell 70:435-448.e5
Fan, Xiaozhou; Alekseyenko, Alexander V; Wu, Jing et al. (2018) Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut 67:120-127
Taylor, Martin S; Altukhov, Ilya; Molloy, Kelly R et al. (2018) Dissection of affinity captured LINE-1 macromolecular complexes. Elife 7:
Bertrand, Anne; Baron, Maria; Hoang, Dung M et al. (2018) In Vivo Evaluation of Neuronal Transport in Murine Models of Neurodegeneration Using Manganese-Enhanced MRI. Methods Mol Biol 1779:527-541
Jung, Seungyoun; Allen, Naomi; Arslan, Alan A et al. (2018) Anti-M├╝llerian hormone and risk of ovarian cancer in nine cohorts. Int J Cancer 142:262-270
Wang, Sophia S; Carrington, Mary; Berndt, Sonja I et al. (2018) HLA Class I and II Diversity Contributes to the Etiologic Heterogeneity of Non-Hodgkin Lymphoma Subtypes. Cancer Res 78:4086-4096
Kirkling, Margaret E; Cytlak, Urszula; Lau, Colleen M et al. (2018) Notch Signaling Facilitates In Vitro Generation of Cross-Presenting Classical Dendritic Cells. Cell Rep 23:3658-3672.e6

Showing the most recent 10 out of 1170 publications